Opportunities and Challenges of HTA Regulation and Joint Clinical Assessments

As the EU Health Technology Assessment (HTA) landscape transforms with the upcoming Joint Clinical Assessment (JCA), what does this mean for timely access to innovative therapies and reducing duplication of efforts across Member States? In this episode, Frédéric Destrebecq, Executive Director of the European Brain Council, sat down with Dr. Dimitrios Georgiopoulos, Senior Vice President and Global Franchise Head for Neurology & Immunology at Merck Healthcare, to discuss the opportunities and challenges of the new Health Technology Assessment Regulation, particularly for orphan and neurological treatments. Join us to explore how this new framework aims to harmonize methodologies, empower patient engagement, and shape a collaborative future for healthcare across the EU.